Abaloparatide Formulation Analysis for Isomer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for osteoporosis, such as bisphosphonates, lead to reduced bone formation, and anabolic agents like teriparatide and abaloparatide have unknown degradants and impurities that affect their efficacy and stability, necessitating improved analytical methods for detection and formulation.
Innovation Solution
Development of improved analytical procedures for evaluating abaloparatide formulations, including detection and quantification of beta-Asp10, cyclo-Asp10, cyclo-Asp17, ATP(3-34), and ATP(4-34), and methods for storing and administering abaloparatide to control these impurities, using high-performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UPLC) with specific solvent systems and buffers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional analytical procedures are used to evaluate abaloparatide formulations, then the analysis is simpler and faster, but previously unknown degradants and impurities (beta-Asp10, cyclo-Asp10, cyclo-Asp17, ATP(3-34), and ATP(4-34)) cannot be detected
Solution Approach 1:
The patent segments the analytical procedure into multiple specialized chromatographic methods, each optimized for detecting specific types of abaloparatide-related peptides. Different HPLC and UPLC methods with specific mobile phases, columns, and detection parameters are developed to resolve and quantify individual degradants and impurities that conventional single-method approaches cannot detect simultaneously.
Solution Approach 2:
The patent systematically varies analytical parameters including mobile phase composition (pH, organic modifier concentration), column temperature, flow rate, and detection wavelength to optimize the separation and detection of different abaloparatide-related peptides. These parameter changes enable the detection of previously unknown degradants with distinct chemical properties.
2Reliability
If abaloparatide is stored without controlled conditions, then storage and handling are simpler, but impurity levels increase affecting therapeutic efficacy and stability
Solution Approach 1:
The patent establishes predetermined storage conditions and handling procedures before impurity formation occurs. Specific temperature ranges, pH buffers, and container materials are selected in advance to prevent degradation. Analytical methods are pre-developed to monitor impurity levels at defined time points, allowing proactive quality control rather than reactive correction.
Solution Approach 2:
The patent implements a feedback mechanism where analytical methods continuously monitor impurity levels in abaloparatide formulations during storage. The detected impurity levels (beta-Asp10, cyclo-Asp10, cyclo-Asp17, ATP(3-34), and ATP(4-34)) provide feedback on formulation stability, allowing adjustment of storage conditions or formulation composition to maintain therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The methods enable precise detection and control of abaloparatide-related peptides, ensuring therapeutic efficacy and stability, allowing for effective treatment of osteoporosis and bone fracture healing by monitoring and managing impurity levels in abaloparatide formulations.
Implementation Method 1
using high-performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UPLC) with specific solvent systems and buffers
Data Source
AI summary
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.